Burnaby, BC, March 2, 2021--Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, reported financial results for the year ended December 31, 2020 and provided a corporate update.
Xenon Pharmaceuticals Inc.
Burnaby, BC (Biotech/Life Sciences) 100-499 Employees In BC (100-499 Employees Total)
Founded: 1996 | Revenues: $15.60 Million
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders.
Burnaby, BC, January 19, 2021--Xenon Pharmaceuticals Inc.(Nasdaq:XENE), a neurology-focused biopharmaceutical company, outlined its key milestone opportunities and plans for a leadership transition in 2021, with all changes anticipated to take effect in June 2021 at the time of the Company's annual meeting of shareholders.
Xenon Pharmaceuticals Inc.
Burnaby, BC (Biotech/Life Sciences) 100-499 Employees In BC (100-499 Employees Total)
Founded: 1996 | Revenues: $15.60 Million
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders.
Burnaby, BC, December 16, 2020--Xenon Pharmaceuticals Inc.(Nasdaq:XENE), a neurology-focused biopharmaceutical company, announced updates on its proprietary and partnered neurology programs at AES2020, the virtual Annual Meeting of the American Epilepsy Society.
Xenon Pharmaceuticals Inc.
Burnaby, BC (Biotech/Life Sciences) 100-499 Employees In BC (100-499 Employees Total)
Founded: 1996 | Revenues: $15.60 Million
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders.
Burnaby, BC, October 9, 2020--Xenon Pharmaceuticals Inc.(Nasdaq:XENE), a neurology-focused biopharmaceutical company, provided regulatory updates on its proprietary pediatric neurology program, XEN496, a Kv7 potassium channel modulator that is a proprietary pediatric formulation of the active ingredient ezogabine being developed for the treatment of KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE).
Xenon Pharmaceuticals Inc.
Burnaby, BC (Biotech/Life Sciences) 100-499 Employees In BC (100-499 Employees Total)
Founded: 1996 | Revenues: $15.60 Million
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders.
Burnaby, BC, August 25, 2020--Xenon Pharmaceuticals Inc.(Nasdaq:XENE), a neurology-focused biopharmaceutical company, announced the appointment of Dr. Chris Von Seggern as Chief Commercial Officer, effective immediately.
Xenon Pharmaceuticals Inc.
Burnaby, BC (Biotech/Life Sciences) 100-499 Employees In BC (100-499 Employees Total)
Founded: 1996 | Revenues: $15.60 Million
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders.
Burnaby, BC, August 13, 2020--Xenon Pharmaceuticals Inc.(Nasdaq:XENE), a neurology-focused biopharmaceutical company, reported its financial results for second quarter ended June 30, 2020 and provided a corporate update.
Xenon Pharmaceuticals Inc.
Burnaby, BC (Biotech/Life Sciences) 100-499 Employees In BC (100-499 Employees Total)
Founded: 1996 | Revenues: $15.60 Million
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders.
Burnaby, BC, May 28, 2020--Xenon Pharmaceuticals Inc.(Nasdaq:XENE), a neurology-focused biopharmaceutical company, reported its financial results for first quarter ended March 31, 2020 and provided a corporate update.
Xenon Pharmaceuticals Inc.
Burnaby, BC (Biotech/Life Sciences) 100-499 Employees In BC (100-499 Employees Total)
Founded: 1996 | Revenues: $15.60 Million
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders.
Burnaby, BC, March 31, 2020--Xenon Pharmaceuticals Inc.(Nasdaq:XENE), a clinical stage biopharmaceutical company, announced equity inducement grants to eight new non-officer employees consisting of an aggregate of 63,200 share options.
Xenon Pharmaceuticals Inc.
Burnaby, BC (Biotech/Life Sciences) 100-499 Employees In BC (100-499 Employees Total)
Founded: 1996 | Revenues: $15.60 Million
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders.
Burnaby, BC, March 9, 2020--Xenon Pharmaceuticals Inc.(Nasdaq:XENE), a clinical stage biopharmaceutical company, reported its financial results for the year ended December 31, 2019 and provided a corporate update.
Xenon Pharmaceuticals Inc.
Burnaby, BC (Biotech/Life Sciences) 100-499 Employees In BC (100-499 Employees Total)
Founded: 1996 | Revenues: $15.60 Million
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders.
Burnaby, BC, January 15, 2020--enon Pharmaceuticals Inc.(Nasdaq:XENE), a clinical stage biopharmaceutical company, provided a corporate update and outlined its key milestone opportunities for 2020.
Xenon Pharmaceuticals Inc.
Burnaby, BC (Biotech/Life Sciences) 100-499 Employees In BC (100-499 Employees Total)
Founded: 1996 | Revenues: $15.60 Million
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders.